Liver specific overexpression of platelet‐derived growth factor‐B accelerates liver cancer development in chemically induced liver carcinogenesis
暂无分享,去创建一个
Thorsten Maass | Peter Schirmacher | Thomas Longerich | Stephan Kanzler | Andreas Teufel | P. Schirmacher | A. Teufel | T. Longerich | D. Strand | S. Kanzler | Peter R Galle | T. Maass | F. Thieringer | Dennis Strand | Torsten Hansen | Florian R Thieringer | Amrit Mann | A. Mann | T. Hansen | P. Galle
[1] Xuri Li,et al. Novel PDGF family members: PDGF-C and PDGF-D. , 2003, Cytokine & growth factor reviews.
[2] Jeanne M Clark,et al. The Epidemiology of Nonalcoholic Fatty Liver Disease in Adults , 2006, Journal of clinical gastroenterology.
[3] P. Schirmacher,et al. Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. , 2006, Journal of hepatology.
[4] P. Bioulac-Sage,et al. [Mechanisms of hepatic fibrogenesis]. , 2002, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.
[5] P. Anthony. Hepatocellular carcinoma: an overview , 2001, Histopathology.
[6] A. Gressner,et al. Pro-fibrogenic potential of PDGF-D in liver fibrosis. , 2007, Journal of hepatology.
[7] David I. Smith,et al. Mutational spectrum of β-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas , 2002, Oncogene.
[8] M. Buendia. Genetics of hepatocellular carcinoma. , 2000, Seminars in cancer biology.
[9] C. Heldin,et al. Mechanism of action and in vivo role of platelet-derived growth factor. , 1999, Physiological reviews.
[10] R. Dirks,et al. Signals controlling the expression of PDGF , 2004, Molecular Biology Reports.
[11] Xinping Tan,et al. Platelet-derived growth factor receptor-α: a novel therapeutic target in human hepatocellular cancer , 2007, Molecular Cancer Therapeutics.
[12] K. McGlynn,et al. Epidemiology and natural history of hepatocellular carcinoma. , 2005, Best practice & research. Clinical gastroenterology.
[13] S. Fan,et al. β‐catenin mutation and overexpression in hepatocellular carcinoma , 2001 .
[14] C. Heldin,et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. , 2001, Cancer research.
[15] Wei Jiang,et al. Wnt/beta-catenin signaling pathway as a novel cancer drug target. , 2004, Current cancer drug targets.
[16] P. Schirmacher,et al. Spontaneous hepatic fibrosis in transgenic mice overexpressing PDGF-A. , 2008, Gene.
[17] F. Huang,et al. Platelet‐derived growth factor‐B increases colon cancer cell growth in vivo by a paracrine effect , 1995, Journal of cellular physiology.
[18] L. Gesualdo,et al. Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. , 1989, The Journal of clinical investigation.
[19] Yusuke Nakamura,et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1 , 2000, Nature Genetics.
[20] L. Qin,et al. Overexpression of Platelet-Derived Growth Factor Receptor α in Endothelial Cells of Hepatocellular Carcinoma Associated with High Metastatic Potential , 2005, Clinical Cancer Research.
[21] M. Kojiro,et al. Expression of vascular endothelial growth factor in human hepatocellular carcinoma , 1998, Hepatology.
[22] H. Kantarjian,et al. Biology of platelet-derived growth factor and its involvement in disease. , 2006, Mayo Clinic proceedings.
[23] R. Eferl,et al. Hepatic tumor–stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge , 2009, Oncogene.
[24] Y. N. Park,et al. Expression of transforming growth factor-beta1 and transforming growth factor-beta receptors in hepatocellular carcinoma and dysplastic nodules. , 2003, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[25] S. Fan,et al. beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. , 2001, Cancer.
[26] E.K. Teo,et al. Hepatocellular Carcinoma: An Asian Perspective , 2002, Digestive Diseases.
[27] B R Johansson,et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. , 1997, Science.
[28] A. Tannapfel,et al. Genes involved in hepatocellular carcinoma: deregulation in cell cycling and apoptosis , 2002, Virchows Archiv.
[29] P. Newman,et al. The Role of PECAM‐1 in Vascular Cell Biology a , 1994, Annals of the New York Academy of Sciences.
[30] Y. N. Park,et al. Expression of Transforming Growth Factor-β1 and Transforming Growth Factor-β Receptors in Hepatocellular Carcinoma and Dysplastic Nodules , 2003, Modern Pathology.
[31] H. Herbst,et al. Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. , 1996, The American journal of pathology.
[32] You-Ming Li,et al. Expression of platelet-derived growth factor-BB in liver tissues of patients with chronic hepatitis B. , 2004, World journal of gastroenterology.
[33] Brygida Berse,et al. Vascular permeability factor (VPF, VEGF) in tumor biology , 1993, Cancer and Metastasis Reviews.
[34] M. Choti,et al. Smad4 overexpression in hepatocellular carcinoma is strongly associated with transforming growth factor beta II receptor immunolabeling. , 2002, Human pathology.
[35] Jin Ding,et al. From cell signaling to cancer therapy , 2007, Acta Pharmacologica Sinica.
[36] K. Jones,et al. Wnt signaling: is the party in the nucleus? , 2006, Genes & development.
[37] M. Konstadoulakis,et al. Strategies for the management of hepatocellular carcinoma , 2007, Nature Clinical Practice Oncology.
[38] J. Shimazaki,et al. Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[39] Y. N. Park,et al. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. , 2000, Archives of pathology & laboratory medicine.
[40] D. Jackson. The unfolding tale of PECAM‐1 , 2003, FEBS letters.
[41] S. Paggi,et al. Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .
[42] Michael Höpfner,et al. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. , 2008, World journal of gastroenterology.
[43] M. Yeh,et al. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[44] N. Gassler,et al. Platelet-derived growth factor isoform expression in carbon tetrachloride-induced chronic liver injury , 2008, Laboratory Investigation.
[45] Philippe Leboulch,et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2 , 2003, Nature Medicine.